Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Update in Ocular Oncology
share announcement

Update in Ocular Oncology

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 5179

Special Issue Editor

Prof. Dr. Miguel A. Materin

E-Mail Website
Guest Editor
Departments of Ophthalmology, Duke University, Durham, NC 27710, USA
Interests: eye cancer; retinoblastoma; ocular tumors; uveal melanoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Even rare, ocular cancer can affect patients of any age or gender. There is increased knowledge in diagnosis, prognosis and treatment of these tumors. Up to 50% of patients with uveal melanoma can die from metastatic disease; however, new modalities of prognosis have been described, which help to identify high-risk patients for metastatic disease. Retinoblastoma is the most common intraocular cancer in children; 90% or more of these patients survive with current treatment in first world countries with up to 50% death in third world countries. Vitreoretinal/CNS lymphoma is one of the most challenging diagnoses in ocular cancer and a common masquerade syndrome. New advances in diagnosis and management are available for ocular surface tumors.

New targeted therapies for systemic cancers have potential side effects on the eye, from common conditions such as dry eye syndrome to loss of vision secondary to exudative retinal detachment or other side effects.

On this special ocular oncology issue, updated information on different ophthalmic tumors will be provided, including diagnosis, prognosis and current options of treatment. Ocular tumors, such as uveal melanoma and retinoblastoma, and ocular side effects of treatment for systemic cancers, such as vitreoretinal lymphoma, are included.

Prof. Dr. Miguel A. Materin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Uveal melanoma
  • Cytogenetics
  • Retinoblastoma
  • Vitreoretinal/CNS lymphoma
  • Ocular surface tumors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1543 KiB  
Article
Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma
by Michael S. Parappilly, Yuki Chin, Riley M. Whalen, Ashley N. Anderson, Trinity S. Robinson, Luke Strgar, Thomas L. Sutton, Patrick Conley, Christopher Klocke, Summer L. Gibbs, Young Hwan Chang, Guanming Wu, Melissa H. Wong and Alison H. Skalet
Cancers 2022, 14(19), 4617; https://doi.org/10.3390/cancers14194617 - 23 Sep 2022
Cited by 8 | Viewed by 2558
Abstract
Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared [...] Read more.
Background: Uveal melanoma is an aggressive cancer with high metastatic risk. Recently, we identified a circulating cancer cell population that co-expresses neoplastic and leukocyte antigens, termed circulating hybrid cells (CHCs). In other cancers, CHCs are more numerous and better predict oncologic outcomes compared to circulating tumor cells (CTCs). We sought to investigate the potential of CHCs as a prognostic biomarker in uveal melanoma. Methods: We isolated peripheral blood monocular cells from uveal melanoma patients at the time of primary treatment and used antibodies against leukocyte and melanoma markers to identify and enumerate CHCs and CTCs by immunocytochemistry. Results: Using a multi-marker approach to capture the heterogeneous disseminated tumor cell population, detection of CHCs was highly sensitive in uveal melanoma patients regardless of disease stage. CHCs were detected in 100% of stage I-III uveal melanoma patients (entire cohort, n = 68), whereas CTCs were detected in 58.8% of patients. CHCs were detected at levels statically higher than CTCs across all stages (p = 0.05). Moreover, CHC levels, but not CTCs, predicted 3 year progression-free survival (p < 0.03) and overall survival (p < 0.04). Conclusion: CHCs are a novel and promising prognostic biomarker in uveal melanoma. Full article
(This article belongs to the Special Issue Update in Ocular Oncology)
►▼ Show Figures

Figure 1

14 pages, 1302 KiB  
Article
Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
by Georgia Levidou, Pawel Gajdzis, Nathalie Cassoux, Piotr Donizy, Christos Masaoutis, Malgorzata Gajdzis, Sophie Gardrat, Alexandros Pergaris, Eougken Danas, Jerzy Klijanienko and Stamatios Theocharis
Cancers 2021, 13(19), 4763; https://doi.org/10.3390/cancers13194763 - 23 Sep 2021
Cited by 11 | Viewed by 1938
Abstract
Background: Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults, exerting high metastatic potential and poor prognosis. Histone deacetylases (HDACs) play a key role in carcinogenesis, and HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical settings. [...] Read more.
Background: Uveal melanoma (UM) represents the most common primary intraocular malignancy in adults, exerting high metastatic potential and poor prognosis. Histone deacetylases (HDACs) play a key role in carcinogenesis, and HDAC inhibitors (HDACIs) are currently being explored as anti-cancer agents in clinical settings. The aim of this study was to evaluate the clinical significance of HDAC-1, -2, -4, and -6 expression in UM. Methods: HDAC-1, -2, -4, and -6 expression was examined immunohistochemically in 75 UM tissue specimens and was correlated with tumors’ clinicopathological characteristics, the presence of tumor-infiltrating lymphocytes (TILS), as well as with our patients’ overall survival (OS). Results: HDAC-2 was the most frequently expressed isoform (66%), whereas we confirmed in addition to the expected nuclear expression the presence of cytoplasmic expression of class I HDAC isoforms, namely HDAC-1 (33%) and HDAC-2 (9.5%). HDAC-4 and -6 expression was cytoplasmic. HDAC-1 nuclear expression was associated with increased tumor size (p = 0.03), HDAC-6 with higher mitotic index (p = 0.03), and nuclear HDAC-2 with epithelioid cell morphology (p = 0.03) and presence of tumor-infiltrating lymphocytes (p = 0.04). The association with the remaining parameters including Monosomy 3 was not significant. Moreover, the presence as well as the nuclear expression pattern of HDAC-2 were correlated with patients’ improved OS and remained significant in multivariate survival analysis. Conclusions: These findings provide evidence for a potential role of HDACs and especially HDAC-2 in the biological mechanisms governing UM evolution and progression. Full article
(This article belongs to the Special Issue Update in Ocular Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop